Patents by Inventor Felix Bormann

Felix Bormann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES FOR CHELATED RADIONUCLIDES
    Publication number: 20220389116
    Abstract: The present application relates to antibodies which bind specifically to chelated radionuclides, including bispecific antibodies. It further relates to the use of such bispecific antibodies in applications such as radioimmunoimaging and radioimmunotherapy. It additionally relates to clearing agents and compositions useful in such methods. The chelated radionuclides may be a DOTAM-lead (Pb) chelate.
    Type: Application
    Filed: April 16, 2019
    Publication date: December 8, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian KLEIN, Pablo UMANA, Alexander HAAS, Barbara WEISER, Florian LIPSMEIER, Guy GEORGES, Sebastian FENN, Joerg MOELLEKEN, Felix BORMANN, Daniela MATSCHEKO
  • ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS
    Publication number: 20220267463
    Abstract: The present invention relates to antibodies which bind to antigens on target cells and which target radionuclides to said cells, and to methods of using the same.
    Type: Application
    Filed: July 10, 2020
    Publication date: August 25, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Pablo UMANA, Sabine IMHOF-JUNG, Alexander HAAS, Christian KLEIN, Sofia FROST, Felix BORMANN, Guy GEORGES, Sebastian FENN, Florian LIPSMEIER, Daniela MATSCHEKO, Joerg MOELLEKEN, Barbara WEISER
  • METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
    Publication number: 20200392253
    Abstract: Herein is reported a method for the generation of multispecific antibodies by a half-antibody exchange reaction between two 2/3-IgGs destabilized in one half by asymmetric perturbing mutations fostering the generation of correctly assemble full length bispecific antibodies. The method can be performed in the absence of reducing agents and does not require hinge region disulfide bonds in the starting 2/3-IgGs.
    Type: Application
    Filed: April 15, 2020
    Publication date: December 17, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Stefan Dengl, Guy Georges, Eike Hoffmann, Klaus Mayer, Felix Bormann